A study has determined that adverse effects leading to treatment discontinuation vary among different blood pressure-lowering drug classes.

Men with rheumatoid arthritis have increased odds for heart failure vs women, particularly those with coronary heart disease. Men with rheumatoid arthritis (RA) have higher odds of developing heart ...

Engaging in moderate to vigorous physical activity concentrated over 1 to 2 days per week may confer survival benefits among adults with OA.

Cancer doctors across the US are running short of essential generic chemotherapy drugs, sparking fear of widespread rationing.

Both non-HDL-C and apolipoprotein B levels independently predict ASCVD risk in patients not receiving statins.

The FDA has approved Tryngolza (olezarsen) to reduce triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia (TG ≥500mg/dL).

Eosinophilic AE-COPD is associated with a lower risk for major adverse cardiovascular events (MACE) compared with noneosinophilic AE-COPD.

Evolocumab therapy reduces the risk for major cardiovascular events in stable patients with prior percutaneous coronary intervention.

Despite an increased risk for cardiovascular disease, women with resolved pregnancy-only hypertension lack adequate preventive health care.

Only 49% of U.S. adults report being “cost secure,” meaning they can pay for the medical visits and treatments they need.

Digoxin therapy may reduce the risk for new-onset or worsening heart failure in patients with symptomatic rheumatic heart disease.

The FDA is asking drugmakers to update the prescribing information on testosterone replacement therapy products to reflect clinical evidence.